For Immediate Release
Chicago, IL – October 19, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Ross Stores Inc. ROST, Roku Inc. ROKU, APA Corp. APA, Corcept Therapeutics Inc. CORT and Halozyme Therapeutics Inc. HALO.
Here are highlights from Friday’s Analyst Blog:
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains
Wall Street has been witnessing an astonishing rally since the beginning of 2023, barring some minor fluctuations. The rally has primarily been driven by the global artificial intelligence (AI) technology boom. Generative and agentic AI have transformed the entire landscape of the information technology sector worldwide.
Consequently, the tech-heavy Nasdaq Composite jumped 43.4%, 28.6% and 20.4%, respectively, in 2023, 2024 and 2025. This trend has continued this year too. The AI momentum is rock-solid and has been expanding the periphery, scale and magnitude day by day. As a result, the tech-heavy index is up 15% year to date.
Despite the fact that the Nasdaq Composite is a tech-laden index, several non-tech Nasdaq-listed stocks have also flourished this year. Investment in these stocks with a Zacks top rank should be fruitful in the last two and half months.
Five such non-tech Nasdaq Composite-listed stocks are: Ross Stores Inc., Roku Inc., APA Corp., Corcept Therapeutics Inc. and Halozyme Therapeutics Inc.. Each of our picks currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Ross Stores Inc.
Ross Stores is well positioned for continued growth, supported by strong sales momentum, customer acquisition and a compelling value proposition. Second-quarter fiscal 2026 sales rose 13%, with broad-based strength across categories and regions.
ROST sees further upside from merchandising, marketing and store-execution initiatives that remain in the early stages. Store expansion adds another growth lever, with 115 openings planned for fiscal 2026. ROST also maintains a strong financial foundation, supported by healthy liquidity and cash generation.
ROST has an expected revenue and earnings growth rate of 12.8% and 32.7%, respectively, for the current year (ending January 2027). The Zacks Consensus Estimate for the current year's earnings has improved 11.7% in the last 60 days.
Roku Inc.
Roku continues to benefit from the shift of viewing and advertising budgets from linear television to streaming, with Platform revenue growth supported by Advertising and Subscriptions. ROKU's scale of more than 100 million streaming households, broader programmatic reach and expanding subscription offering support continued monetization of the Roku Experience.
The new Home Screen and AI-powered search could further improve content discovery, retention and advertising opportunities as the rollout expands. ROKU is broadening its advertising model across programmatic demand, enterprise campaigns and self-service tools. Advertising revenues increased 24.8% year over year in the second quarter of 2026 to $672.8 million, while advertising gross margin rose to 62.4%.
ROKU has an expected revenue and earnings growth rate of 18.5% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 2.2% over the last 30 days.
APA Corp.
APA offers a favorable setup, supported by stronger capital efficiency, cost savings and visible long-term growth. GranMorgu remains on track for first oil in mid-2028, while the Permian is delivering higher U.S. oil guidance without added capital.
Better cash conversion and ROIC point to improved funding flexibility and capital productivity, helping APA reduce debt while supporting shareholder returns. APA's earnings remain cyclical, however, and commodity prices can materially affect cash flow. Gas-trading returns are market-sensitive.
Net debt also remains meaningful, though deleveraging is progressing. APA is lowering its underlying cost structure across operations. APA's stronger operating efficiency, disciplined spending and long-term growth potential outweigh risks.
APA has an expected revenue and earnings growth rate of -1.1% and 53.6%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 1.6% over the last 30 days.
Corcept Therapeutics Inc.
Corcept Therapeutics' lead marketed drug, Korlym, approved for treating Cushing's syndrome, continues to see strong demand, a trend likely to persist through the rest of 2026. Though still in early days, the recent FDA approval and launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for treating platinum-resistant ovarian cancer should support CORT's revenue diversification and growth.
CORT's recent resubmission of the NDA for relacorilant in Cushing's syndrome is also encouraging. Relacorilant has been designated as an orphan drug for the treatment of Cushing's syndrome by the FDA and the European Commission.
Corcept Therapeutics has an expected revenue and earnings growth rate of 50.3% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 5.1% over the last 30 days.
Halozyme Therapeutics Inc.
Halozyme Therapeutics has collaboration deals related to its ENHANZE technology with several large pharma companies that generate royalties and milestone payments. This, in turn, is driving HALO's top line, which is expected to continue for the rest of 2026.
Robust demand for argenx's Vyvgart Hytrulo and the subcutaneous formulation of Johnson & Johnson's Darzalex is boosting HALO's royalties and the top line. The momentum is likely to continue for the rest of 2026. HALO is also focused on signing new collaboration deals to aid growth.
Halozyme Therapeutics has an expected revenue and earnings growth rate of 35.1% and more than 100%, respectively, for the current year. The Zacks Consensus Estimate for the current year's earnings has improved 0.8% over the last seven days.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
APA Corporation (APA): Free Stock Analysis Report
Ross Stores, Inc. (ROST): Free Stock Analysis Report
Halozyme Therapeutics, Inc. (HALO): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
Roku, Inc. (ROKU): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).